OncologyImmuno-oncologyImmunology & inflammationRespiratory disease PopPKExposure-response

Atezolizumab real-world population PK

Reference paper ↗

A two-compartment population PK model representing atezolizumab concentration and exposure with body weight, albumin, sex, and anti-therapeutic-antibody covariates.

Therapeutic
Atezolizumab
Modality
Monoclonal antibody
Target
PD-L1 / CD274
Disease
Advanced or recurrent non-small cell lung cancer
Model type
PopPK, Exposure-response

Complete model workspace

Checking workspace access…

Parameters
23
States
3
Equations
3
Derived outputs
10

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

Article median

How do real-world patient covariates change atezolizumab concentration and exposure? Explore this intervention regimen through Central atezolizumab concentration, Peripheral atezolizumab concentration, Cumulative atezolizumab exposure.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–82 day; step 0.05

InputDefaultAvailable range
Population systemic clearance0.2 L/day0.1–0.3 L/day
Population central distribution volume3.28 L1.64–4.92 L
Population intercompartmental clearance0.546 L/day0.273–0.819 L/day
Population peripheral distribution volume3.63 L1.815–5.445 L
Body weight58.6 kg29.3–87.9 kg

Expected readouts

Central atezolizumab concentration · Peripheral atezolizumab concentration · Exposure (AUC)

Adjustable model parameters

This public explorer exposes 5 curated parameters. Sign in to edit all 23 declared model parameters.

More key parameters (1)

How the model represents the biology

A two-compartment population PK model representing atezolizumab concentration and exposure with body weight, albumin, sex, and anti-therapeutic-antibody covariates.

How do clinical covariates shape real-world atezolizumab exposure?Intravenous atezolizumab enters a central pool, exchanges with a peripheral pool, undergoes linear covariate-adjusted clearance, and accumulates exposure. Weight, albumin, sex, tumor burden, and anti-therapeutic-antibody status modify disposition.BIOLOGY OVERVIEWHow do clinical covariates shape real-world atezolizumab exposure?IV atezolizumabInfusion to central amountCentral exposureAtezolizumab concentrationPeripheral poolReversible distributionLinear clearanceCovariate-adjusted lossClinical covariatesWeight, albumin, sex, tumor,ATAGCumulative exposureCentral concentration integralPRIMARY READOUTSCentral atezolizumab concentrationCentral atezolizumab conce…Peripheral concentrationPeripheral concentrationCumulative exposureCumulative exposure

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: PD-L1 binding, receptor occupancy, immune activation, tumor response, efficacy, target-mediated disposition, and time-varying clearance are not represented.

Modeled relationships (7)
  • IV atezolizumab → Central exposure: IV input (flow)
  • Central exposure ↔ Peripheral pool: distribution (reversible exchange)
  • Central exposure → Linear clearance: linear CL (loss)
  • Clinical covariates → Linear clearance: scales CL (modulation)
  • Clinical covariates → Central exposure: scales V1 (modulation)
  • Clinical covariates → Peripheral pool: scales V2 (modulation)
  • Central exposure → Cumulative exposure: integrates C (production)

Modeled relationships: IV atezolizumab to Central exposure: IV input (flow); Central exposure reversibly exchanges with Peripheral pool: distribution (reversible exchange); Central exposure to Linear clearance: linear CL (loss); Clinical covariates to Linear clearance: scales CL (modulation); Clinical covariates to Central exposure: scales V1 (modulation); Clinical covariates to Peripheral pool: scales V2 (modulation); Central exposure to Cumulative exposure: integrates C (production).

Primary readouts: Central atezolizumab concentration; Peripheral concentration; Cumulative exposure.

Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID yagishita_2024_atezolizumab_jtail_real_world_pk.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics